semaglutide for parkinson's Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment GLP-1 drug shows little benefit

Administered as a once-weekly subcutaneous injection , Ozempic has demonstrated effectiveness in improving glycaemic control in type 2 diabetes

(Peptide Sciences) Importantly: selective removal of senescent cells without significant impact on non-senescent cells

10.1152/ajpheart.00209.2014

Issue: No measurable vision improvement after 3 months Potential causes: Unrealistic expectations (expecting improvement vs slowed decline), advanced disease with minimal salvageable tissue, inadequate dosing or inconsistent use, wrong peptide for specific condition, peptides genuinely ineffective for individual, progression monitoring inadequate missing subtle benefits